Latest Media Releases - Letter N (Page 11) | Finance News Network

Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Noxopharm, Results of Meeting (ASX:NOX)

A summary of valid and eligible proxies received for the above meeting was as follows... For more information, download the attached PDF.

Noxopharm, NOX EGM Chairman's Address and Presentation (ASX:NOX)

Noxopharm Limited (ASX: NOX) (‘Noxopharm’ or the ‘Company’) today releases the Chairman’s Address and Presentation for today’s Extraordinary General Meeting. F...read more

Noxopharm Announce Veyonda® Research to be Shared at Two Major Oncology Conferences Enhancing Radiotherapy in Prostate Cancer Treatment (ASX:NOX)

Australian drug development company NoxopharmTM to present interim results on new prostate cancer treatment at specialist oncology conferences in Australia and overseas SYDNEY, 12 Sept 201...read more

Noxopharm, Appendix 4E and Audited Financial Statements FY19 (ASX:NOX)

To view the report, download the attached PDF.

Noxopharm, More Evidence that Veyonda Enhances RT in Prostate Cancer (ASX:NOX)

Noxopharm (ASX: NOX) (‘Noxopharm’ or the ‘Company’) today announced the interim three month results from the second part of the DARRT-1 study on its proprietary treatment Vey...read more

Noxopharm, NOX Receives FY19 Federal Government R&D Tax Rebate (ASX:NOX)

Noxopharm Limited (ASX: NOX) is pleased to announce that it has received $3.71M cash rebate as part of the Federal Government R&D Tax Incentive Scheme. Greg van Wyk, Noxopharm Chief Executive Of...read more

Noxopharm Announce Pre-Clinical Evidence Confirms Veyonda Abscopal Effect (ASX:NOX)

Veyonda® is being developed as a transformative anti-cancer treatment (DARRT) in combination with radiotherapy to produce off-target responses known as an abscopal effect Pre-clinical...read more

Noxopharm, Notice of Extraordinary General Meeting/Proxy Form (ASX:NOX)

You are being asked to consider and then approve a series of resolutions, all related to the funding facility into which we recently entered. The Board considered a number of funding options, but se...read more

Noxopharm August 2019 Corporate Presentation (ASX:NOX)

Noxopharm Limited (ASX: NOX) (‘Noxopharm’ or the ‘Company’) today releases its August 2019 Corporate Presentation ahead of Australian and U.S. roadshows. The Presentation ...read more

Noxopharm announce Appendix 4C - June 2019 Quarter (ASX:NOX)

Positive results from two prostate cancer trials Phase 2 trial design gaining momentum Investigational New Drug Application to be submitted to FDA in Q3 2019 Pipeline developi...read more

Noxopharm Announces AU$26 Million Funding Facility (ASX:NOX)

Key Highlights AU$4,000,000 initial funding Equity placement component of up to additional AU$22,000,000 in ordinary shares over 12 month Flexible funding package leadin...read more

Noxopharm Announces Board Changes Ahead of Corporate Growth (ASX:NOX)

Board Changes Ahead of Corporate Growth Key Highlights Experienced pharma executive, Dr Beata Niechoda, joins Noxopharm Board Mr John Moore becomes Executive Chairman of Noxopha...read more

Noxopharm, SNMMI 2019 Conference LuPIN Presentation Released (ASX:NOX)

Noxopharm Ltd (ASX: NOX) (‘Noxopharm’ or the ‘Company’) is pleased to provide to the market the recording of the oral presentation given to the SNMMI 2019 Annual Meeting (Soc...read more

U.S. Conference Hears of Positive Interim Data from LuPIN Trial (ASX:NOX)

KEY HIGHLIGHTS LuPIN study enrolling heavily pre-treated men with progressive late-stage prostate cancer (mCRPC) Clinical data shows combining Veyonda with radiopharmaceutical, 177Lu-PSM...read more

Noxopharm, NOX Subsidiary, Nyrada Inc, Receives R&D Rebate (ASX:NOX)

Noxopharm (ASX: NOX) (‘Noxopharm’) is pleased to announce that its majority-owned U.S. subsidiary company, Nyrada Inc (‘Nyrada’), has received a cash rebate of $486.338K unde...read more

Viewing: 151 - 165 of 200 Previous | Next